ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0661

Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Abstract Number: 1527

Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Abstract Number: 0921

Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
Abstract Number: 1300

Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Abstract Number: 0930

Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
Abstract Number: 1080

Effect of Triage by a Rheumatologist in a Primary Care Setting
Abstract Number: 1529

Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Abstract Number: 1679

Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic
Abstract Number: 1674

Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Abstract Number: 0599

Effectiveness of a Provider Led Intervention on Medication Adherence in an Urban Lupus Clinic
Abstract Number: 0243

Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Abstract Number: 1442

Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Abstract Number: 1077

Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Abstract Number: 1120

Effectiveness of Stretching and Bracing for the Treatment of Osteoarthritis-associated Joint Contractures Prior to Joint Replacement: A Systematic Review
Abstract Number: 1926

Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].